Relief Therapeutics Holding AG (RLFTF)

[PennyWorld]

I noticed this on the YF board. Assessment by the "Valuation Lab"

I like this Valuation Lab observation: "Relief is developing a diversified product portfolio in rare metabolic, pulmonary, and connective tissue disorders, all with high margins. The recent US launch of PKU GOLIKE and the approval and future launch of ACER-001 should provide a boost to short and medium-term revenues. The successful development of RLF-100 in rare pulmonary disorders such as pulmonary sarcoidosis and acute respiratory distress syndrome (ARDS), RLF-TD011 in epidermolysis bullosa (EB), and RLF-OD032 in PKU should boost medium and long-term revenues substantially."